Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Hypertens ; 30(7): 673-682, 2017 Jul 01.
Article in English | MEDLINE | ID: mdl-28338787

ABSTRACT

BACKGROUND: Preeclampsia (PE) is a hypertensive disorder of pregnancy characterized by hypertension and proteinuria. The HELLP syndrome is the most severe form of PE. The aim of the present study was to determine different potential biomarkers that may help us perform an early diagnosis of the disease, assess on the severity of the disease, and/or predict maternal or fetal adverse outcomes. METHODS: We measured serum levels of total and fetal circulating cell-free DNA (cfDNA), soluble endoglin, soluble form of vascular endothelial growth factor receptor, and placental growth factor in a healthy control group of pregnant women (n = 26), patients with mild (n = 37) and severe PE (n = 25), and patients with HELLP syndrome (n = 16). RESULTS: We observed a gradual and strong relationship between all the biomarkers mentioned and the range of severity of PE, with the highest levels in patients with HELLP syndrome. Nevertheless, only the values of total cfDNA were able to significantly differentiate severe PE and HELLP syndrome (20957 ± 2784 vs. 43184 ± 8647 GE/ml, P = 0.01). Receiver operating characteristic (ROC) curves were constructed (i) for the healthy group with respect to the groups with PE and (ii) for patients with PE with respect to the group with HELLP syndrome; sensitivity and specificity values at different cutoff levels were calculated in each case. The maximum ROC area under the curve value for PE and HELLP syndrome (with respect to controls) was 0.91 (P < 0.001). CONCLUSIONS: The measured biomarkers of cell damage, angiogenesis, and antiangiogenesis may reflect the severity of PE, with higher levels in patients who develop HELLP syndrome. In addition, these biomarkers may also help predict adverse fetal and maternal outcomes.


Subject(s)
Angiogenic Proteins/blood , Cell-Free Nucleic Acids/blood , HELLP Syndrome/blood , Pre-Eclampsia/blood , Adult , Area Under Curve , Case-Control Studies , Cell-Free Nucleic Acids/genetics , Diagnosis, Differential , Endoglin/blood , Female , HELLP Syndrome/diagnosis , HELLP Syndrome/genetics , Humans , Placenta Growth Factor/blood , Pre-Eclampsia/diagnosis , Pre-Eclampsia/genetics , Predictive Value of Tests , Pregnancy , Pregnancy Trimester, Third/blood , ROC Curve , Severity of Illness Index , Up-Regulation , Vascular Endothelial Growth Factor Receptor-1/blood
2.
Hypertension ; 64(1): 165-71, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24752434

ABSTRACT

Preeclampsia is a pregnancy-related disorder associated with increased cardiovascular risk for the offspring. Endothelial colony-forming cells (ECFCs) are a subset of circulating endothelial progenitor cells that participate in the formation of vasculature during development. However, the effect of preeclampsia on fetal levels of ECFCs is largely unknown. In this study, we sought to determine whether cord blood ECFC abundance and function are altered in preeclampsia. We conducted a prospective cohort study that included women with normal (n=35) and preeclamptic (n=15) pregnancies. We measured ECFC levels in the umbilical cord blood of neonates and characterized ECFC phenotype, cloning-forming ability, proliferation, and migration toward vascular endothelial growth factor-A and fibroblast growth factor-2, in vitro formation of capillary-like structures, and in vivo vasculogenic ability in immunodeficient mice. We found that the level of cord blood ECFCs was statistically lower in preeclampsia than in control pregnancies (P=0.04), a reduction that was independent of other obstetric factors. In addition, cord blood ECFCs from preeclamptic pregnancies required more time to emerge in culture than control ECFCs. However, once derived in culture, ECFC function was deemed normal and highly similar between preeclampsia and control, including the ability to form vascular networks in vivo. This study demonstrates that preeclampsia affects ECFC abundance in neonates. A reduced level of ECFCs during preeclamptic pregnancies may contribute to an increased risk of developing future cardiovascular events.


Subject(s)
Endothelial Cells/pathology , Fetal Blood/cytology , Pre-Eclampsia/pathology , Stem Cells/pathology , Adult , Cell Movement/drug effects , Cell Movement/physiology , Cell Proliferation/drug effects , Endothelial Cells/drug effects , Female , Fibroblast Growth Factor 2/pharmacology , Humans , Pregnancy , Prospective Studies , Risk Factors , Vascular Endothelial Growth Factor A/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...